We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
Read MoreHide Full Article
Investors in Intra-Cellular Therapies, Inc. (ITCI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 17, 2019 $17.5 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Intra-Cellular Therapies shares, but what is the fundamental picture for the company? Currently, Intra-Cellular Therapies is a Zacks Rank #3 (Hold) in the Medical – Biomedical and Genetics industry that ranks in the Top 28% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while one has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 89 cents per share to a loss of 90 cents in that period.
Given the way analysts feel about Intra-Cellular Therapies right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the NFLX earnings report completely free. See it here: Bartosiak: Trading Netflix's (NFLX) Earnings with Options or check out the embedded video below for more details:
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
Investors in Intra-Cellular Therapies, Inc. (ITCI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 17, 2019 $17.5 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Intra-Cellular Therapies shares, but what is the fundamental picture for the company? Currently, Intra-Cellular Therapies is a Zacks Rank #3 (Hold) in the Medical – Biomedical and Genetics industry that ranks in the Top 28% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while one has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 89 cents per share to a loss of 90 cents in that period.
Given the way analysts feel about Intra-Cellular Therapies right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the NFLX earnings report completely free. See it here: Bartosiak: Trading Netflix's (NFLX) Earnings with Options or check out the embedded video below for more details: